Lakefront Biotherapeutics NV (LKFT) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Lakefront Biotherapeutics NV (LKFT) closed at USD 29.40 on 2026-10-14, a change of -6.2 % over the past year, with a market capitalization of USD 1.96B.

Lakefront Biotherapeutics NV recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Lakefront Biotherapeutics NV key figures

Previous close

USD 29.40 (2026-10-14)

1-year change

-6.2 %

Market cap

USD 1.96B

Enterprise value

USD 37.07B

P/E ratio (trailing)

2.77

P/E ratio (forward)

-25.22

EPS (trailing)

10.82

EPS (forward)

-1.19

PEG ratio

n/a

Price to book

10.76

Revenue growth

-81.5 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

10.63

Employees

196

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Lakefront Biotherapeutics NV

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Lakefront Biotherapeutics NV and compare it with other stocks.